You are here

  • Home
  • Archive
  • Volume 24, Issue 4
  • L-type Amino Acid Transporter 1 Expression Increases in Well-Differentiated but Decreases in Poorly Differentiated Endometrial Endometrioid Adenocarcinoma and Shows an Inverse Correlation With p53 Expression

Article Text

Article menu
Download PDFPDF
Basic Science
L-type Amino Acid Transporter 1 Expression Increases in Well-Differentiated but Decreases in Poorly Differentiated Endometrial Endometrioid Adenocarcinoma and Shows an Inverse Correlation With p53 Expression
  1. Jun Watanabe, MD, PhD*,
  2. Yoshihito Yokoyama, MD, PhD†,
  3. Masayuki Futagami, MD, PhD†,
  4. Hideki Mizunuma, MD, PhD†,
  5. Haruhiko Yoshioka, PhD*,
  6. Kiyotada Washiya, PhD*,
  7. Kiyomi Hana, MT‡,
  8. Hitoshi Endou, MD, PhD§∥ and
  9. Isao Okayasu, MD, PhD‡
  1. *Division of Medical Life Sciences, Department of Pathologic Analysis, Graduate School of Health Sciences, and
  2. †Department of Obstetrics and Gynecology, Graduate School of Medicine, Hirosaki University, Hirosaki;
  3. ‡Department of Pathology, Kitasato University School of Medicine, Sagamihara; and
  4. §J-Pharma Co, Ltd; and
  5. ∥Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Tokyo, Japan.
  1. Address correspondence and reprint requests to Jun Watanabe, MD, PhD, Division of Medical Life Sciences, Department of Pathologic Analysis, Hirosaki University Graduate School of Health Sciences, 66-1 Hon-Cho, Hirosaki 036-8564, Japan. E-mail: watajun{at}cc.hirosaki-u.ac.jp.

Abstract

Objectives The aims of this study were to determine whether the altered L-type amino acid transporter 1 (LAT1) expression is related to clinicopathologic factors, expressions of Ki-67, p53, estrogen receptor, and progesterone receptor and clarify the significance of LAT1 as a prognostic factor and the novel possibility of using it to treat endometrial endometrioid adenocarcinoma.

Methods The LAT1 expression was analyzed immunohistochemically in atrophic (6 cases), secretory phase (6 cases), proliferative phase endometria (6 cases), atypical hyperplasia (6 cases), and endometrioid adenocarcinoma (26 well-differentiated [G1], 17 moderately differentiated, and 11 poorly differentiated [G3] adenocarcinoma patients).

Results The LAT1 expression was observed in the cell membrane. Its expression increased in the atrophic, secretory, and proliferative phases of the endometrium in that order. There was no difference between the proliferative phase endometrium, atypical hyperplasia, and G1 adenocarcinoma. The LAT1 expression in G1 adenocarcinoma was significantly higher than that in G3 adenocarcinoma. The LAT1 expression was inversely correlated with p53 expression but not with those of Ki-67, estrogen receptor, or progesterone receptor.

Conclusions It is suggested that the significance of LAT1 as a prognostic factor is low because LAT expression was low in G3 adenocarcinoma, not correlated with the International Federation of Gynecology and Obstetrics stage and proliferative activity and inversely correlated with p53. The LAT1 inhibitors can be used as anticancer drugs for G1 and moderately differentiated adenocarcinoma that express high LAT1.

  • Endometrial endometrioid adenocarcinoma
  • LAT1
  • Histological grade
  • p53

https://doi.org/10.1097/IGC.0000000000000123

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • This study was supported by a grant for Hirosaki University Institutional Research (2013).

    • The authors declare no conflicts of interest.